Myriad says Prolaris predicts risk of metastasis in men with prostate cancer
Myriad Genetics announced publication of results from a large study that demonstrated the Prolaris test can accurately predict the 10-year risk of metastases in men newly diagnosed with localized prostate cancer. The study was published in journal Prostate Cancer and Prostatic Diseases. The large pooled analysis included 1,062 men with localized prostate cancer who were definitively treated with surgery or radiation. The primary objective was to evaluate ability of the Prolaris test and the Prolaris test combined with clinical information to predict 10-year risk of progression to metastatic disease. The analysis demonstrated the Prolaris test was the strongest independent predictor of progression to metastatic disease, and men were approximately three times more likely to develop metastatic disease with each unit increase in the Prolaris test score. When the Prolaris test score was combined with clinical information the results were even more highly prognostic, and men were up to four times more likely to develop metastases with each unit increase in the test score.